Gene therapy with inducible nitric oxide synthase protects against myocardial infarction via a cyclooxygenase-2-dependent mechanism

Keyphrases

• Gene Therapy 100%
• Myocardial Infarction 100%
• Inducible Nitric Oxide Synthase 100%
• Cyclooxygenase-2 100%
• NO Synthase 100%
• Cardioprotection 21%
• Late Preconditioning 21%
• Protein Expression 14%
• Infarct 14%
• Gene Transfer 14%
• Ischemia-reperfusion Injury 14%
• Infarct Size 14%
• NO Synthase 2 14%
• Protein Activity 7%
• Rous Sarcoma Virus 7%
• Complementary DNA (cDNA) 7%
• Myocardial Ischemia 7%
• Cyclooxygenase-2 Inhibitors 7%
• Functional Modules 7%
• Systemic Hemodynamics 7%
• Prostanoids 7%
• Adenovirus Type 5 7%
• Downstream Effectors 7%
• Ischemic Preconditioning 7%
• E3 Region 7%
• Continuous Intravenous Infusion 7%
• NS-398 7%
• NO Donors 7%
• Stress-responsive 7%
• Sparing Effect 7%
• Intramyocardial Injection 7%
• 2-form 7%
• Close-coupling 7%

Biochemistry, Genetics and Molecular Biology

• Gene Therapy 100%
• Cyclooxygenase 100%
• Nitric Oxide Synthase 100%
• Isoform 88%
• Enzyme 11%
• Protein Expression 11%
• Reperfusion 11%
• Upregulation 5%
• Promoter Region 5%
• Hemodynamic 5%
• Prostanoid 5%
• Human Adenovirus 5 5%
• Rous Sarcoma Virus 5%
• Ischemic Preconditioning 5%
• NS-398 5%